MX2020002995A - Metodo de conjugacion de transglutaminasa y ligador. - Google Patents
Metodo de conjugacion de transglutaminasa y ligador.Info
- Publication number
- MX2020002995A MX2020002995A MX2020002995A MX2020002995A MX2020002995A MX 2020002995 A MX2020002995 A MX 2020002995A MX 2020002995 A MX2020002995 A MX 2020002995A MX 2020002995 A MX2020002995 A MX 2020002995A MX 2020002995 A MX2020002995 A MX 2020002995A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- aax
- linker
- amino acid
- conjugation method
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un método para generar un conjugado de anticuerpo-carga útil por medio de una transglutaminasa microbiana (MTG). El método comprende un paso para conjugar un ligador que tiene un residuo de amina primaria, el ligador tiene la estructura de péptido (mostrada en la dirección N->C) (Aax)m-(Aax)(NH2)-(Aax)n-B-(Aax)o, o (Aax)m-B-(Aax)n-(Aax)(NH2)-(Aax)o, a un residuo Gln comprendido en la cadena pesada o ligera de un anticuerpo. Aax(NH2) es un aminoácido, derivado de aminoácido o mimético de aminoácido que comprende una cadena lateral que tiene un grupo amina primaria (Figura 1).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17191825 | 2017-09-19 | ||
| GBGB1800878.9A GB201800878D0 (en) | 2018-01-19 | 2018-01-19 | Transglutaminase conjugation method and linker |
| PCT/EP2018/075350 WO2019057772A1 (en) | 2017-09-19 | 2018-09-19 | METHOD FOR CONJUGATING TRANSGLUTAMINASE AND BINDING SEQUENCE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002995A true MX2020002995A (es) | 2020-07-22 |
Family
ID=63678617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002995A MX2020002995A (es) | 2017-09-19 | 2018-09-19 | Metodo de conjugacion de transglutaminasa y ligador. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US12128110B2 (es) |
| EP (1) | EP3684419A1 (es) |
| JP (2) | JP2020534030A (es) |
| KR (1) | KR102697329B1 (es) |
| CN (1) | CN111163809B (es) |
| AU (1) | AU2018337671B2 (es) |
| CA (1) | CA3075218A1 (es) |
| MX (1) | MX2020002995A (es) |
| NZ (1) | NZ762376A (es) |
| WO (1) | WO2019057772A1 (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018337671B2 (en) | 2017-09-19 | 2021-03-04 | Paul Scherrer Institut | Transglutaminase conjugation method and linker |
| PT3865155T (pt) * | 2020-02-13 | 2023-01-02 | Orano Med | Processo para modificação específica de local de um anticorpo |
| US12227593B2 (en) | 2020-05-20 | 2025-02-18 | Janssen Biotech, Inc. | Site-specific conjugation of glycosylated monoclonal antibodies with transglutaminase |
| MX2022014530A (es) * | 2020-05-20 | 2023-02-27 | Janssen Biotech Inc | Métodos para la conjugación específica del sitio de proteínas que contienen dominios fc glicosilados. |
| EP4213886A1 (en) | 2020-09-18 | 2023-07-26 | Araris Biotech AG | Transglutaminase conjugation method with amino acid-based linkers |
| CN116801910A (zh) * | 2020-10-25 | 2023-09-22 | 阿拉里斯生物技术股份公司 | 生产抗体-接头偶联物的手段和方法 |
| JP7789396B2 (ja) | 2020-10-25 | 2025-12-22 | アラリス バイオテック アーゲー | 抗体-リンカーコンジュゲートを生成するための手段および方法 |
| MX2023004935A (es) * | 2020-11-10 | 2023-07-07 | Regeneron Pharma | Conjugados de anticuerpos y selenio. |
| AU2021389027A1 (en) * | 2020-11-30 | 2023-06-29 | Anbition S.R.L. | Multi-specific human albumin nanoparticles decorated with antibody fragments and loaded with cytotoxics |
| AU2022307460A1 (en) | 2021-07-09 | 2024-01-04 | Bright Peak Therapeutics Ag | Checkpoint inhibitors conjugated to il-2, and uses thereof |
| US20230201364A1 (en) | 2021-07-09 | 2023-06-29 | Bright Peak Therapeutics Ag | Antibody conjugates and manufacture thereof |
| WO2023281482A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Cd20-targeted il-2 and its uses |
| KR20240034221A (ko) | 2021-07-09 | 2024-03-13 | 브라이트 피크 테라퓨틱스 아게 | 염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드 |
| AU2022306788A1 (en) | 2021-07-09 | 2024-01-04 | Bright Peak Therapeutics Ag | Conjugates of checkpoint inhibitors with il-2, and uses thereof |
| EP4410830A4 (en) * | 2021-09-30 | 2026-07-08 | Ajinomoto Kk | CONJUGATE OF ANTIBODY AND FUNCTIONAL SUBSTANCE OR ITS SALT, DERIVATIVE OF ANTIBODY AND COMPOUND OR ITS SALTS FOR USE IN THE PRODUCTION OF A CONJUGATE OR ITS SALT |
| EP4422695A1 (en) | 2021-10-25 | 2024-09-04 | Araris Biotech AG | Methods for producing antibody-linker conjugates |
| KR20240150807A (ko) | 2022-02-22 | 2024-10-16 | 아라리스 바이오테크 아게 | 2개 이상의 페이로드를 포함하는 펩티드 링커 |
| JP2025505835A (ja) * | 2022-02-22 | 2025-02-28 | アーデーセー セラピューティクス ソシエテ アノニム | トリミングされたn-グリカンを含むfc領域でのトランスグルタミナーゼを伴うコンジュゲーション方法 |
| AU2023226512A1 (en) | 2022-02-23 | 2024-08-29 | Bright Peak Therapeutics Ag | Immune antigen specific il-18 immunocytokines and uses thereof |
| EP4489862A1 (en) | 2022-03-09 | 2025-01-15 | Merck Patent GmbH | Anti-ceacam5 antibodies and conjugates and uses thereof |
| EP4526437A1 (en) * | 2022-05-20 | 2025-03-26 | Curie Co. Inc. | Pro-peptide variants for modulating activity of transglutaminases |
| US20240424127A1 (en) | 2023-01-11 | 2024-12-26 | Bright Peak Therapeutics Ag | Il-7 polypeptides, immunocytokines comprising same, and uses thereof |
| WO2024150174A1 (en) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
| EP4692115A1 (en) * | 2023-04-04 | 2026-02-11 | Ajinomoto Co., Inc. | Antibody-functional substance conjugate, antibody derivative, and compound, or salts thereof |
| WO2024240162A1 (en) | 2023-05-23 | 2024-11-28 | Shanghai Allygen Biologics Co., Ltd. | Pd-l1 and trop-2 targeting conjugates comprising effector molecules and uses thereof |
| EP4673182A1 (en) * | 2023-06-04 | 2026-01-07 | Araris Biotech AG | Dual payload antibody drug conjugates for the treatment of cancer |
| US20250186597A1 (en) | 2023-08-23 | 2025-06-12 | Bright Peak Therapeutics Ag | Targeted immune activation with il-18 immunocytokines |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| WO2025082990A1 (en) | 2023-10-15 | 2025-04-24 | Araris Biotech Ag | Antibody-drug conjugates using two different types of topoisomerase i inhibitors |
| WO2025242909A1 (en) | 2024-05-24 | 2025-11-27 | Paul Scherrer Institut | CD30-targeting antibody-radioligand conjugates and their therapeutic use |
| WO2026013234A1 (en) | 2024-07-10 | 2026-01-15 | Araris Biotech Ag | Triple-payload antibody-drug conjugates (adcs) |
| EP4684803A1 (en) | 2024-07-25 | 2026-01-28 | CeMM - Forschungszentrum für Molekulare Medizin GmbH | Antibody conjugated chemical inducers of degradation of rbm39 and therapeutic uses thereof |
| WO2026069134A1 (en) | 2024-09-26 | 2026-04-02 | Bright Peak Therapeutics Ag | Human therapy with il-18 immunocytokines |
| WO2026083296A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains |
| WO2026083295A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains |
| WO2026093350A1 (en) | 2024-10-30 | 2026-05-07 | Merck Patent Gmbh | Antibody-linker-lipid conjugate |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
| US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
| US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
| JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| WO1994012520A1 (en) * | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
| FI990180A7 (fi) | 1996-08-12 | 1999-03-08 | Celgene Corp | Uusia immunoterapeuttisia aineita ja niiden käyttö sytokiini-tasojen pienentämiseksi |
| US5969516A (en) | 1997-07-25 | 1999-10-19 | Ntc, Inc. | Electrical circuit interrupter device locator |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| EP1499885B1 (en) * | 2001-08-01 | 2009-10-21 | Cellomics, Inc. | Novel fusion proteins and assays for molecular binding |
| US6660510B2 (en) | 2001-12-17 | 2003-12-09 | Food Industry Research And Development | Transglutaminase gene of Streptoverticillium ladakanum and the transglutaminase encoded therefrom |
| JP2005522514A (ja) | 2002-04-10 | 2005-07-28 | ジェネンテック・インコーポレーテッド | 抗her2抗体改変体 |
| WO2004043493A1 (en) | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
| US7955814B2 (en) | 2003-01-17 | 2011-06-07 | Danisco A/S | Method |
| EP2290085B1 (en) | 2003-01-17 | 2017-12-13 | DuPont Nutrition Biosciences ApS | Method for the in situ production of an emulsifier in a foodstuff |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| EP2123756B1 (en) | 2007-02-15 | 2014-06-04 | Ajinomoto Co., Inc. | Transglutaminase having disulfide bond introduced therein |
| WO2008102007A1 (en) | 2007-02-22 | 2008-08-28 | Novo Nordisk Health Care Ag | Transglutaminase variants with improved specificity |
| PT2474557E (pt) | 2007-07-16 | 2014-12-03 | Genentech Inc | Anticorpos e imunoconjugados anti-cd79b e métodos de utilização |
| EP2197443A4 (en) | 2007-09-26 | 2014-01-01 | Gemin X Pharmaceuticals Canada Inc | COMPOSITIONS AND METHOD FOR LEADING NAD + MIRRORS USING A NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE HEMMER |
| DK2657253T3 (en) | 2008-01-31 | 2017-10-09 | Genentech Inc | Anti-CD79b antibodies and immune conjugates and methods of use |
| MX2011010469A (es) | 2009-04-08 | 2012-03-14 | Deutsches Krebsforsch | Radicales de enlace al objetivo, armados con amatoxina para el tratamiento del cancer. |
| EP3192529B1 (en) | 2009-04-08 | 2020-03-25 | Faulstich, Heinz, Dr. | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy |
| EP2963111A1 (en) | 2009-12-22 | 2016-01-06 | Lifebond Ltd | Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices |
| WO2011119484A1 (en) | 2010-03-23 | 2011-09-29 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| AR082886A1 (es) | 2010-09-03 | 2013-01-16 | Forma Therapeutics Inc | Compuestos y composiciones farmaceuticas que los contienen |
| ES2874306T3 (es) | 2010-09-29 | 2021-11-04 | Agensys Inc | Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12 |
| ES2402254T3 (es) | 2010-09-30 | 2013-04-30 | Heidelberg Pharma Ag | Conjugados de amatoxinas con ligadores mejorados |
| CA2813411C (en) * | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| EP2497499A1 (en) | 2011-03-10 | 2012-09-12 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkages |
| EP2771349B1 (en) | 2011-09-16 | 2020-02-26 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| WO2013049830A2 (en) | 2011-09-30 | 2013-04-04 | The Washington University | Tip-1 and grp-78 binding peptides and method of identifying peptide receptors |
| CA2858806A1 (en) | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of polypeptides |
| EP2872894B1 (en) * | 2012-07-13 | 2019-04-17 | Innate Pharma | Screening of conjugated antibodies |
| EP2774624A1 (en) | 2013-03-04 | 2014-09-10 | Heidelberg Pharma GmbH | Amatoxin derivatives |
| EP2777714A1 (en) | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
| US10611824B2 (en) | 2013-03-15 | 2020-04-07 | Innate Pharma | Solid phase TGase-mediated conjugation of antibodies |
| KR20160042871A (ko) * | 2013-06-21 | 2016-04-20 | 이나뜨 파르마, 에스.아. | 폴리펩티드의 효소적 콘쥬게이션 |
| US10195289B2 (en) | 2013-07-31 | 2019-02-05 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates using transglutaminase |
| WO2015054060A1 (en) | 2013-10-09 | 2015-04-16 | Eli Lilly And Company | Novel pyridyloxyacetyl tetrahydroisoquinoline compounds useful as nampt inhibitors |
| JP6865584B2 (ja) | 2013-12-23 | 2021-04-28 | コヴァラブ | 化合物の共有結合性コンジュゲーションのためのmTG基質 |
| KR20190072663A (ko) | 2014-04-25 | 2019-06-25 | 리나트 뉴로사이언스 코프. | 약물이 고도로 로딩된 항체-약물 접합체 |
| CA2951887A1 (en) | 2014-06-12 | 2015-12-17 | Cspc Dophen Corporation | Homogenous antibody drug conjugates via enzymatic methods |
| HUE049325T2 (hu) | 2014-08-28 | 2020-09-28 | Pfizer | Stabilitás modulátor linker antitest-hatóanyag konjugátumokhoz történõ alkalmazásra |
| ES2871624T3 (es) | 2014-12-19 | 2021-10-29 | Hoffmann La Roche | Transglutaminasas microbianas, sustratos para las mismas y procedimientos para el uso de las mismas |
| US20180028682A1 (en) | 2015-02-09 | 2018-02-01 | Nbe Therapeutics Ag | Maytansine-drug conjugates of her-2 specific binding proteins generated by site specific sortase-enzyme mediated conjugation |
| ES2736106T3 (es) | 2015-03-10 | 2019-12-26 | Bristol Myers Squibb Co | Anticuerpos que se pueden conjugar mediante la transglutaminasa y conjugados producidos a partir de ellos |
| EP3069734A1 (en) | 2015-03-17 | 2016-09-21 | Exiris S.r.l. | Cryptophycin-based antibody-drug conjugates with novel self-immolative linkers |
| MX2017017138A (es) * | 2015-06-23 | 2018-04-30 | Bayer Pharma AG | Conjugados homogeneos especificos de sitio con inhibidores de ksp. |
| WO2017025179A1 (en) | 2015-08-07 | 2017-02-16 | Merck Patent Gmbh | A transglutamine tag for efficient site-specific bioconjugation |
| US10689458B2 (en) | 2015-11-30 | 2020-06-23 | Pfizer Inc. | Site specific HER2 antibody drug conjugates |
| EP4032902A1 (en) | 2015-12-18 | 2022-07-27 | Eisai R&D Management Co., Ltd. | C-terminal lysine conjugated immunoglobulins |
| EP3272864A1 (en) | 2016-07-20 | 2018-01-24 | Paul Scherrer Institut | Solid-phase immobilization of microbial transglutaminase mtg on microbeads for protein conjugation |
| US10906957B2 (en) * | 2016-09-27 | 2021-02-02 | Epicentrx, Inc. | Immunomodulatory fusion proteins |
| KR20230008269A (ko) | 2017-08-07 | 2023-01-13 | 엔비이-테라퓨틱스 아게 | 생체 내 내성이 높은 항체 약물 결합체 |
| AU2018337671B2 (en) | 2017-09-19 | 2021-03-04 | Paul Scherrer Institut | Transglutaminase conjugation method and linker |
| WO2019082020A1 (en) | 2017-10-27 | 2019-05-02 | Pfizer Inc. | ANTIBODIES AND CONJUGATES CD123-SPECIFIC ANTIBODIES AND USES THEREOF |
| CN113613679A (zh) | 2019-03-19 | 2021-11-05 | 保罗·谢勒学院 | 基于甘氨酸的接头的转谷氨酰胺酶缀合方法 |
| EP4213886A1 (en) | 2020-09-18 | 2023-07-26 | Araris Biotech AG | Transglutaminase conjugation method with amino acid-based linkers |
| JP7789396B2 (ja) | 2020-10-25 | 2025-12-22 | アラリス バイオテック アーゲー | 抗体-リンカーコンジュゲートを生成するための手段および方法 |
-
2018
- 2018-09-19 AU AU2018337671A patent/AU2018337671B2/en active Active
- 2018-09-19 NZ NZ762376A patent/NZ762376A/en unknown
- 2018-09-19 JP JP2020537053A patent/JP2020534030A/ja active Pending
- 2018-09-19 EP EP18773746.5A patent/EP3684419A1/en active Pending
- 2018-09-19 CA CA3075218A patent/CA3075218A1/en active Pending
- 2018-09-19 US US16/648,636 patent/US12128110B2/en active Active
- 2018-09-19 MX MX2020002995A patent/MX2020002995A/es unknown
- 2018-09-19 CN CN201880060599.4A patent/CN111163809B/zh active Active
- 2018-09-19 KR KR1020207011370A patent/KR102697329B1/ko active Active
- 2018-09-19 WO PCT/EP2018/075350 patent/WO2019057772A1/en not_active Ceased
-
2024
- 2024-03-07 JP JP2024034922A patent/JP2024081670A/ja active Pending
- 2024-03-14 US US18/604,709 patent/US20240350656A1/en active Pending
- 2024-10-28 US US18/928,274 patent/US20250161479A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111163809A (zh) | 2020-05-15 |
| KR102697329B1 (ko) | 2024-08-23 |
| US20210128743A1 (en) | 2021-05-06 |
| EP3684419A1 (en) | 2020-07-29 |
| CA3075218A1 (en) | 2019-03-28 |
| CN111163809B (zh) | 2024-07-02 |
| KR20200057046A (ko) | 2020-05-25 |
| JP2024081670A (ja) | 2024-06-18 |
| AU2018337671B2 (en) | 2021-03-04 |
| US20250161479A1 (en) | 2025-05-22 |
| US12128110B2 (en) | 2024-10-29 |
| AU2018337671A1 (en) | 2020-03-26 |
| JP2020534030A (ja) | 2020-11-26 |
| NZ762376A (en) | 2022-08-26 |
| US20240350656A1 (en) | 2024-10-24 |
| WO2019057772A1 (en) | 2019-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120249T1 (el) | Αντισωμα ανταγωνιστης κατευθυνομενο εναντι πεπτιδιου σχετιζομενου με το γονιδιο καλσιτονινης | |
| CU20190099A7 (es) | Dominio de unión a antígeno anti-trbc1, y receptor de antígeno quimérico, anticuerpo, acoplador biespecífico de células t y conjugado anticuerpo-fármaco que comprenden el mismo | |
| BR112021016984A2 (pt) | Receptores de antígeno quimérico direcionados a dll3 e agentes de ligação | |
| AR065083A1 (es) | Hepcidina, antagonistas de la hepcidina y metodos de uso | |
| AR110853A2 (es) | Un método para preparar el conjugado de péptido insulinotrópico, y una composición farmacéutica que comprende a dicho conjugado de péptido insulinotrópico | |
| NZ610239A (en) | Cross-linkers and their uses | |
| ATE412688T1 (de) | Hochfunktionelle, hochverzweigte polyharnstoffe | |
| CO6180445A2 (es) | Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3 | |
| DK2327719T3 (da) | Hybrid- og tandemekspression af neisseria-proteiner | |
| AR070202A1 (es) | Anticuerpos anti- trkb mejorados | |
| NZ742916A (en) | C-terminal lysine conjugated immunoglobulins | |
| AR058419A1 (es) | Compuestos de nucleosidos triciclicos para tratar infecciones virales | |
| PH12014501783B1 (en) | Anti-lipoarabinomannan antibody and immunoassay for acid-fast bacillary infection using the antibody | |
| CY1110651T1 (el) | Παραγωγα της ν-'(1,5-διφαινυλ-1η- πυραζολ-3-υλ)μεθυλ σουλφοναμιδης με μια συγγενεια για τους υποδοχεις cb1 | |
| MX338940B (es) | Identificacion de epitopos ige novedosos. | |
| AR047496A1 (es) | Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina | |
| CY1114504T1 (el) | Συνθεσεις τιγεκυκλινης και μεθοδοι παρασκευης | |
| HUE031655T2 (hu) | Csontot targetáló alkálikus foszfatáz, készletek és eljárások alkalmazásukra | |
| TR201905924T4 (tr) | Si̇ni̇r hücreleri̇ni̇ hedefleyen taşiyici | |
| TR200103337T2 (tr) | Protez inhibitrleri olarak yeni bileçikler ve bileçimler | |
| CO5560528A2 (es) | Agentes de contraste de objetivo multimetrico con base en peptidos | |
| CL2023001101A1 (es) | Medios y métodos para producir conjugados de ligador-anticuerpo. | |
| EA202190264A1 (ru) | КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn | |
| EA200870208A1 (ru) | Конструкт однодоменного антитела | |
| CY1108321T1 (el) | Καινοφανη παραγωγα δικαρβοξυλικου οξεος |